Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
$187.10
$187.10
$122.26
▼
$195.00
N/AN/A1,957 shsN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
C$90.00
+3.0%		C$104.18
C$75.00
▼
C$169.90
N/AN/A414 shs391 shs
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$31.85
-0.7%		$34.60
$21.68
▼
$37.52
$34.44BN/A44,096 shs65,144 shs
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
$11.80
-1.7%		$11.48
$9.22
▼
$12.68
$3.80BN/A13,208 shs2,785 shs
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
0.00%0.00%0.00%0.00%+26.38%
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
0.00%-4.10%-9.43%-19.06%+35.78%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00%-1.41%-9.51%-7.69%+26.77%
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
0.00%+2.10%+2.24%+13.56%+2.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
$187.10
$187.10
$122.26
▼
$195.00
N/AN/A1,957 shsN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
C$90.00
+3.0%		C$104.18
C$75.00
▼
C$169.90
N/AN/A414 shs391 shs
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$31.85
-0.7%		$34.60
$21.68
▼
$37.52
$34.44BN/A44,096 shs65,144 shs
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
$11.80
-1.7%		$11.48
$9.22
▼
$12.68
$3.80BN/A13,208 shs2,785 shs
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
0.00%0.00%0.00%0.00%+26.38%
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
0.00%-4.10%-9.43%-19.06%+35.78%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00%-1.41%-9.51%-7.69%+26.77%
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
0.00%+2.10%+2.24%+13.56%+2.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
0.00
N/AN/AN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
0.00
N/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
2.00
HoldN/AN/A
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest OTSKY, SNPHY, AZNCF, and CMOPF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/13/2026
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
3/31/2026
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
N/AN/AN/AN/AN/AN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$16.51B2.07$2.97 per share10.74$19.33 per share1.65
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
N/A$0.82229.29N/AN/AN/AN/AN/AN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$2.43B$2.3713.4415.1711.3515.01%12.33%9.11%7/30/2026 (Estimated)
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
N/AN/A0.10N/AN/AN/AN/AN/AN/A

Latest OTSKY, SNPHY, AZNCF, and CMOPF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/28/2026Q1 2026
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$0.4306$0.59+$0.1594$0.59$3.78 billion$3.96 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
$2.801.50%N/A343.14%N/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/AN/AN/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$0.260.82%N/A10.97%N/A
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
$48.30409.31%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
N/AN/AN/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/AN/AN/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.05
2.17
1.67
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
40.87%
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
0.05%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
N/A
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
N/A
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZNCF
AstraZeneca
83,500N/AN/ANot Optionable
Cosmo Pharmaceuticals stock logo
CMOPF
Cosmo Pharmaceuticals
319N/AN/ANot Optionable
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
37,7581.07 billionN/ANot Optionable
Santen Pharmaceutical Co., Ltd. stock logo
SNPHY
Santen Pharmaceutical
4,144322.29 millionN/ANot Optionable

Recent News About These Companies

Santen Pharmaceutical Co Ltd ADR SNPHY
May 14, 2026  |  morningstar.comM
Santen Pharmaceutical Co., - Depositary Receipt (SNPHY) Price Target Decreased by 10.74% to 13.32
November 9, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/santen-pharmaceutical-co-depositary-receipt-snphy-price-target-decreased-by-1074-to-1332/ar-AA1Q57YH
Santen Pharmaceutical 1H Net Y13.94B Vs Net Y18.77B
November 6, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/santen-pharmaceutical-1h-net-y13-94b-vs-net-y18-77b-64fec638
Santen Pharmaceutical to Cancel 19.8 Million Treasury Shares
November 6, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-to-cancel-19-8-million-treasury-shares?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical Updates on Share Buyback Progress
November 4, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-updates-on-share-buyback-progress-4?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical Reports Progress on Share Buyback Initiative
October 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-reports-progress-on-share-buyback-initiative?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical Updates on Share Buyback Progress
September 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-updates-on-share-buyback-progress-3?utm_source=marketbeat.com&utm_medium=referral
Santen and RemeGen sign licence deal for retinal disease injection
August 19, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/santen-and-remegen-sign-licence-deal-for-retinal-disease-injection/ar-AA1KOYUe
Santen Pharmaceutical Co (SNPHY) - Investing.com UK
August 8, 2025  |  uk.investing.comhttps://uk.investing.com/equities/santen-pharmaceutical-co-historical-data
Santen Pharmaceutical Updates on Share Buyback Progress
July 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-updates-on-share-buyback-progress?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical FY Net Y36.26B Vs Net Y26.64B
May 13, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/santen-pharmaceutical-fy-net-y36-26b-vs-net-y26-64b-6694c474
China’s NMPA authorises Santen’s glaucoma treatment application
April 7, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/china-s-nmpa-authorises-santen-s-glaucoma-treatment-application/ar-AA1Cto5T
Santen Pharmaceutical to Cancel 5 Million Treasury Shares
February 6, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-to-cancel-5-million-treasury-shares?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical Co. Revises Year-End Dividend Forecast
February 6, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/santen-pharmaceutical-co-revises-year-end-dividend-forecast?utm_source=marketbeat.com&utm_medium=referral
Santen Pharmaceutical Announces Share Buyback Plan
November 8, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/santen-pharmaceutical-announces-share-buyback-plan-1033968431
Santen Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34B
August 6, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/santen-pharmaceutical-co-ltd-gaap-eps-of-yen-2785-revenue-of-yen-7234b/ar-AA1ojRzQ
Here's what to expect from Santen Pharmaceutical's earnings report
August 6, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/santen_pharmaceutical-q1-earnings-preview-1033638779
SNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023
May 17, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/snphy-stock-earnings-santen-pharmaceutical-for-q4-of-2023/?cc=marketbeat&cp=pdtk
Santen Pharmaceutical earnings preview: what to expect
May 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/santen_pharmaceutical-stock-quarter-earnings-preview-q4-1033347409
Santen Pharmaceutical Co Ltd
April 23, 2024  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca OTCMKTS:AZNCF

$187.10 0.00 (0.00%)
As of 06/12/2026

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Cosmo Pharmaceuticals stock logo

Cosmo Pharmaceuticals OTCMKTS:CMOPF

C$90.00 +2.60 (+2.97%)
As of 03:58 PM Eastern

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Otsuka stock logo

Otsuka OTCMKTS:OTSKY

$31.85 -0.21 (-0.66%)
As of 03:59 PM Eastern

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

Santen Pharmaceutical stock logo

Santen Pharmaceutical OTCMKTS:SNPHY

$11.80 -0.20 (-1.67%)
As of 02:52 PM Eastern

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas